Tobias Mühlethaler

Dr. Tobias Mühlethaler

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2021 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
TMTobias Mühlethaler
Tobias Mühlethaler
DGDario Gioia
Dario Gioia
APAndrea E. Prota
Andrea E. Prota
MSMay E. Sharpe
May E. Sharpe
ACAndrea Cavalli
Andrea Cavalli
MSMichel Steinmetz
Michel Steinmetz
Tubulin plays essential roles in vital cellular activities and is the target of a wide range of proteins and ligands. Here, using a combined computational and crystallographic fragment screening approach, we addressed the question of how many binding sites exist in tubulin. We identified 27 distinct sites, of which 11 have not been described previously, and analyzed their relationship to known tubulin–protein and tubulin–ligand interactions. We further observed an intricate pocket communication network and identified 56 chemically diverse fragments that bound to 10 distinct tubulin sites. Our results offer a unique structural basis for the development of novel small molecules for use as tubulin modulators in basic research applications or as drugs. Furthermore, our method lays down a framework that may help to discover new pockets in other pharmaceutically important targets and characterize them in terms of chemical tractability and allosteric modulation.

25 April 2022 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
TMTobias Mühlethaler
Tobias Mühlethaler
LMLampros Milanos
Lampros Milanos
JOJose Antonio Ortega
Jose Antonio Ortega
TBThorsten B. Blum
Thorsten B. Blum
DGDario Gioia
Dario Gioia
MSMichel Steinmetz
Michel Steinmetz
In this study, we capitalized on our previously performed crystallographic fragment screen and developed the antitubulin small molecule Todalam with only two rounds of straightforward chemical synthesis. Todalam binds to a novel tubulin site, disrupts microtubule networks in cells, arrests cells in G2/M, induces cell death, and synergizes with vinblastine. The compound destabilizes microtubules by acting as a molecular plug that sterically inhibits the curved‐to‐straight conformational switch in the α‐tubulin subunit, and by sequestering tubulin dimers into assembly incompetent oligomers. Our results describe for the first time the generation of a fully rationally designed small molecule tubulin inhibitor from a fragment, which displays a unique molecular mechanism of action. They thus demonstrate the usefulness of tubulin‐binding fragments as valuable starting points for innovative antitubulin drug and chemical probe discovery campaigns.

26 July 2021 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
FJFinith Jernigan
Finith Jernigan
ABArthur Branstrom
Arthur Branstrom
JBJohn D. Baird
John D. Baird
LCLiangxian Cao
Liangxian Cao
MDMandar Dali
Mandar Dali
MWMarla Weetall
Marla Weetall
PTC596 is an investigational small-molecule tubulin-binding agent. Unlike other tubulin-binding agents, PTC596 is orally bioavailable and is not a P-glycoprotein substrate. So as to characterize PTC596 to position the molecule for optimal clinical development, the interactions of PTC596 with tubulin using crystallography, its spectrum of preclinical in vitro anticancer activity, and its pharmacokinetic–pharmacodynamic relationship were investigated for efficacy in multiple preclinical mouse models of leiomyosarcomas and glioblastoma. Using X-ray crystallography, it was determined that PTC596 binds to the colchicine site of tubulin with unique key interactions. PTC596 exhibited broad-spectrum anticancer activity. PTC596 showed efficacy as monotherapy and additive or synergistic efficacy in combinations in mouse models of leiomyosarcomas and glioblastoma. PTC596 demonstrated efficacy in an orthotopic model of glioblastoma under conditions where temozolomide was inactive. In a first-in-human phase I clinical trial in patients with cancer, PTC596 monotherapy drug exposures were compared with those predicted to be efficacious based on mouse models. PTC596 is currently being tested in combination with dacarbazine in a clinical trial in adults with leiomyosarcoma and in combination with radiation in a clinical trial in children with diffuse intrinsic pontine glioma.

5 May 2021 in Angewandte Chemie
Verified
Journal Article
Open access
PDF file
TMTobias Mühlethaler
Tobias Mühlethaler
DGDario Gioia
Dario Gioia
APAndrea E. Prota
Andrea E. Prota
MSMay E. Sharpe
May E. Sharpe
ACAndrea Cavalli
Andrea Cavalli
MSMichel Steinmetz
Michel Steinmetz
Tubulin plays essential roles in vital cellular activities and is the target of a wide range of proteins and ligands. Here, using a combined computational and crystallographic fragment screening approach, we addressed the question of how many binding sites exist in tubulin. We identified 27 distinct sites, of which 11 have not been described previously, and analyzed their relationship to known tubulin–protein and tubulin–ligand interactions. We further observed an intricate pocket communication network and identified 56 chemically diverse fragments that bound to 10 distinct tubulin sites. Our results offer a unique structural basis for the development of novel small molecules for use as tubulin modulators in basic research applications or as drugs. Furthermore, our method lays down a framework that may help to discover new pockets in other pharmaceutically important targets and characterize them in terms of chemical tractability and allosteric modulation.

13 March 2023 in Molecules
Verified
Journal Article
Open access
PDF file
BWBeatrice Wagner
Beatrice Wagner
FBFlorian P. C. Binder
Florian P. C. Binder
XJXiaohua Jiang
Xiaohua Jiang
TMTobias Mühlethaler
Tobias Mühlethaler
RPRoland C. Preston
Roland C. Preston
BEBeat Ernst
Beat Ernst
The d-GlcNAc moiety in sialyl Lewisx (sLex, 1) acts predominantly as a linker to position the d-Gal and the l-Fuc moieties in the bioactive spatial orientation. The hypothesis has been made that the NHAc group of GlcNAc pushes the fucose underneath the galactose and, thus, contributes to the stabilization of the bioactive conformation of the core of sLex (1). To test this hypothesis, GlcNAc mimetics consisting of (R,R)-1,2-cyclohexanediols substituted with alkyl and aryl substituents adjacent to the linking position of the fucose moiety were synthesized. To explore a broad range of extended and spatially demanding R-groups, an enzymatic approach for the synthesis of 3-alkyl/aryl-1,2-cyclohexanediols (3b-n) was applied. These cyclohexanediol derivatives were incorporated into the sLex mimetics 2b-n. For analyzing the relationship of affinity and core conformation, a 1H NMR structural-reporter-group concept was applied. Thus, the chemical shift of H-C5Fuc proved to be a sensitive indicator for the degree of pre-organization of the core of this class of sLex mimetics and therefore could be used to quantify the contribution of the R-groups.

25 April 2022 in Angewandte Chemie
Verified
Journal Article
Open access
TMTobias Mühlethaler
Tobias Mühlethaler
LMLampros Milanos
Lampros Milanos
JOJose Antonio Ortega
Jose Antonio Ortega
TBThorsten B. Blum
Thorsten B. Blum
DGDario Gioia
Dario Gioia
MSMichel Steinmetz
Michel Steinmetz
In this study, we capitalized on our previously performed crystallographic fragment screen and developed the antitubulin small molecule Todalam with only two rounds of straightforward chemical synthesis. Todalam binds to a novel tubulin site, disrupts microtubule networks in cells, arrests cells in G2/M, induces cell death, and synergizes with vinblastine. The compound destabilizes microtubules by acting as a molecular plug that sterically inhibits the curved‐to‐straight conformational switch in the α‐tubulin subunit, and by sequestering tubulin dimers into assembly incompetent oligomers. Our results describe for the first time the generation of a fully rationally designed small molecule tubulin inhibitor from a fragment, which displays a unique molecular mechanism of action. They thus demonstrate the usefulness of tubulin‐binding fragments as valuable starting points for innovative antitubulin drug and chemical probe discovery campaigns.